Business Context and Reporting Period
This Form 8-K Current Report from Glucotrack, Inc. (GCTK) covers events occurring on September 11, 2026, and September 14, 2026. The filing details the results of a special meeting of stockholders held to approve significant equity issuances required to comply with Nasdaq Listing Rule 5635(d) and an amendment to a warrant agreement.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on corporate governance actions and capital structure adjustments rather than operational financial performance.
Material Changes and Corporate Actions
- Stockholder Approval: On September 11, 2026, stockholders approved two proposals to authorize the issuance of shares representing more than 20% of the company's outstanding common stock.
- Proposal 1 (ELOC): Approved the issuance of shares to White Lion Capital, LLC under an ELOC Purchase Agreement, including commitment shares and warrant exercises.
- Proposal 2 (Bridge Financing): Approved the issuance of shares upon conversion of senior secured convertible promissory notes (Bridge Notes) and exercise of warrants (Bridge Warrants) issued to Bridge Investors.
- Warrant Amendment: On September 14, 2026, the Company amended Common Warrants issued in a private placement on August 4, 2026. The amendment restricts the exercise of these warrants until stockholder approval is obtained for the issuance of the underlying shares.
Voting Results and Quorum
As of the record date, there were 10,578,822 shares of Common Stock outstanding. A quorum was established with 3,661,960 votes represented (approximately 34.61% of eligible votes).
| Proposal | Votes For | Votes Against | Abstentions | Outcome |
|---|---|---|---|---|
| 1. ELOC Issuance | 3,101,374 | 228,374 | 332,212 | Approved |
| 2. Bridge Financing Issuance | 3,106,894 | 226,850 | 328,216 | Approved |
| 3. Adjournment | N/A | N/A | N/A | Not Presented |
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the warrant exercise is now contingent upon the completed stockholder approval. The primary contingency resolved by this filing is the regulatory requirement to obtain stockholder consent for significant equity dilution.
Key Facts for Investor Verification
- Verify the total number of shares issuable under the ELOC Purchase Agreement and Bridge Notes to assess the magnitude of dilution.
- Confirm the exercise price and expiration dates of the Common Warrants amended on September 14, 2026.
- Review the definitive proxy statement (Schedule 14A) filed on August 10, 2026, for detailed terms of the financing agreements.
- Monitor subsequent filings for the actual issuance of shares and the impact on the company's capitalization table.